

# Three dimensions of the amyloid hypothesis: time, space and ‘wingmen’

Erik S Musiek & David M Holtzman

**The amyloid hypothesis, which has been the predominant framework for research in Alzheimer’s disease (AD), has been the source of considerable controversy. The amyloid hypothesis postulates that amyloid- $\beta$  peptide ( $A\beta$ ) is the causative agent in AD. It is strongly supported by data from rare autosomal dominant forms of AD. However, the evidence that  $A\beta$  causes or contributes to age-associated sporadic AD is more complex and less clear, prompting criticism of the hypothesis. We provide an overview of the major arguments for and against the amyloid hypothesis. We conclude that  $A\beta$  likely is the key initiator of a complex pathogenic cascade that causes AD. However, we argue that  $A\beta$  acts primarily as a trigger of other downstream processes, particularly tau aggregation, which mediate neurodegeneration.  $A\beta$  appears to be necessary, but not sufficient, to cause AD. Its major pathogenic effects may occur very early in the disease process.**

In their original edition of the amyloid cascade hypothesis in 1992, Hardy and Higgins postulated that “amyloid- $\beta$  protein ( $A\beta$ )...is the causative agent in Alzheimer’s disease (AD) pathology and that neurofibrillary tangles, cell loss, vascular damage and dementia follow as a direct result of this deposition”<sup>1</sup>. Although two decades of research have revealed many layers of complexity, we will argue that the bulk of data still supports a role for  $A\beta$  as the primary initiator of AD pathogenesis. We will discuss data that support the amyloid hypothesis, address some key arguments against the amyloid hypothesis and present an updated framework for AD pathogenesis that attempts to reconcile the existing data. It has become clear that  $A\beta$  does not exert its effects in a vacuum and that a complex network of pathologic processes converge to produce the neuropathologic and clinical syndrome that is AD. However, multiple lines of evidence still support the concept that  $A\beta$  aggregation has a unique and critical role as the key initiator of AD pathology. By our interpretation of the existing data,  $A\beta$  appears to be necessary, but not sufficient, for AD, although it may be necessary and sufficient for cerebral amyloid angiopathy (CAA). This argument over the role of  $A\beta$  has important implications regarding the development of therapies, the allocation of research funding, and the focus of public and private research efforts.

Department of Neurology, Knight Alzheimer’s Disease Research Center, and Hope Center for Neurological Disorders, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA. Correspondence should be addressed to D.M.H. ([holtzman@neuro.wustl.edu](mailto:holtzman@neuro.wustl.edu)).

Received 5 November 2014; accepted 23 March 2015; published online 26 May 2015; doi:10.1038/nn.4018

## Genetic factors that increase $A\beta$ aggregation cause AD

The strongest data supporting the role of  $A\beta$  as disease initiator come from human genetics. Autosomal dominant familial AD (fAD) is caused by mutations in three genes, *APP*, *PSEN1* and *PSEN2*, which are all integrally involved in  $A\beta$  production<sup>2</sup>. *APP* encodes the amyloid precursor protein, which is the precursor to  $A\beta$ , whereas *PSEN1* and *PSEN2* encode Presenilin 1 and 2, catalytic subunits of the  $\gamma$ -secretase complex that cleaves *APP* to generate  $A\beta$ . fAD mutations lead to accelerated accumulation of  $A\beta$  plaques and cause early-onset dementia, CAA or both<sup>2–6</sup>. Duplication of the *APP* locus on chromosome 21 increases  $A\beta$  production through increased gene dosage and causes age-related dementia with brain parenchymal  $A\beta$  deposits and CAA<sup>7–9</sup>. Down syndrome patients, who have trisomy 21 and thus have an extra copy of *APP*, develop age-related amyloid plaque deposition and dementia in an *APP*-dependent manner<sup>10</sup>. In general, pathogenic mutations in all three genes are specifically clustered in regions that serve to increase the level of amyloidogenic *APP* cleavage by  $\beta$ - or  $\gamma$ -secretase or increase the relative production of amyloidogenic  $A\beta_{1–42}$  versus shorter  $A\beta$  species<sup>2,11–13</sup>. Notably, several *APP* mutations that reside in the middle of the  $A\beta$  coding region have been identified that cause fAD or CAA by increasing the aggregation propensity or inhibiting degradation of the  $A\beta$  peptide and do not affect  $A\beta$  production<sup>5,6</sup>. This suggests that it is  $A\beta$  aggregation, rather than some other alteration in *APP* processing or presenilin function, which instigates fAD. Thus, fAD provides an opportunity to examine a pure  $A\beta$ -driven disease in relatively young, often healthy patients. Consistent with the amyloid hypothesis, fAD patients first develop fibrillar amyloid plaques, then subsequently accumulate neurofibrillary tau pathology, neuronal loss and dementia<sup>14,15</sup>. Thus, it is relatively easy to argue that the amyloid hypothesis, or a variant of it, is generally true for fAD. Notably, fAD-linked mutations clearly affect age of onset, but do not strongly affect rate of progression of symptomatic disease. Although some of these mutations cause large increases in the production of  $A\beta$ , they do not substantially accelerate progression, suggesting that  $A\beta$  serves as an initiator of pathology, but not a major mediator of downstream neurodegeneration<sup>16</sup>.

Fortunately, fAD is extremely rare, and the vast majority of AD cases are considered to be sporadic (sAD). The genetics of sAD are more complex, and the strongest genetic risk factor is *APOE*. The *APOE*  $\epsilon 4$  allele increases risk for AD and CAA, and the  $\epsilon 2$  allele decreases risk for AD relative to the  $\epsilon 3$  allele<sup>17,18</sup>. Approximately 20–25% of the population carries at least one copy of ApoE4, which increases the risk of AD by ~4-fold (as compared to those with the more common ApoE3/E3 genotype), whereas 2% of the population carries two E4 alleles, imparting a ~12-fold increased risk<sup>19</sup>. Although ApoE4 appears to exert a variety of effects in the brain, it is a strong

modulator of A $\beta$  pathology, and knock-in mice expressing human ApoE4 along with FAD-linked APP transgenes have greatly increased A $\beta$  plaque pathology and reduced A $\beta$  clearance<sup>19,20</sup>, whereas human ApoE2-expressing mice have decreased A $\beta$  plaque pathology<sup>21</sup>. Numerous studies have demonstrated accelerated amyloid plaque accumulation in human ApoE4 carriers, and preclinical studies have shown that ApoE influences A $\beta$  metabolism, with ApoE4 promoting amyloid aggregation and deposition<sup>20–25</sup>. Reducing ApoE levels, either genetically or with antibody therapy, also reduces A $\beta$  plaque burden in mice<sup>26–29</sup>. Furthermore, human ApoE4 is associated with pathogenic changes in cerebrospinal fluid (CSF) A $\beta$ <sub>42</sub> in cognitively normal subjects, but not changes in tau, again suggesting that ApoE4 exerts its main effects in AD by modulating A $\beta$  upstream of tau<sup>23,30</sup>. Thus, the predominant genetic risk factor for sAD clearly exacerbates A $\beta$  aggregation. Recently, a rare protective mutation in the APP gene, which diminishes amyloidogenic A $\beta$  production, has been identified in humans and linked to a decreased risk of developing AD<sup>31</sup>, providing another strong genetic link between A $\beta$  and sAD.

### Tau pathology and neurodegeneration: anatomical discord

One key argument against the amyloid hypothesis is based on the poor correlation, both temporally and anatomically, between A $\beta$  plaque deposition, neuronal death and clinical symptoms in sAD. Neuroanatomically, fibrillar A $\beta$  deposition occurs first and most severely in regions such as the precuneus and frontal lobes, whereas neuronal death begins and occurs most readily in the entorhinal cortex and hippocampus, regions with relatively few A $\beta$  plaques<sup>32,33</sup>. Tau pathology correlates much more closely with neuronal loss, both spatially and temporally, than amyloid plaques<sup>33–36</sup>. According to the work of Braak and others, A $\beta$  pathology appears to begin in the cortex and spread inward, whereas tau pathology exhibits an opposite progression<sup>32,37</sup>. This has prompted critics to suggest that A $\beta$  must not mediate neurodegeneration in AD and is merely a bystander. If this were true, one would expect that, in fAD, in which disease pathogenesis is more clearly driven by A $\beta$ , that there would be a stronger anatomical correlation between plaque deposition and neuronal loss. This is not the case, as fAD pathology closely resembles that of sAD, with A $\beta$  plaques anatomically disconnected from areas of severe neuronal loss<sup>14,15</sup>. Thus, genetic data again demonstrate that it is possible for A $\beta$  to drive tau pathology and neuronal loss without inherently obvious anatomic colocalization between plaques and areas of neurodegeneration. This anatomic disconnect between fibrillar A $\beta$  plaques, neurofibrillary tangles and neuronal loss is still not fully explained, but appears to be consistent between fAD and sAD.

In sAD, the relationship between A $\beta$  and tau pathology is complex, but ultimately supportive of the amyloid hypothesis. Aggregated, phosphorylated tau pathology is present in the brainstem and entorhinal cortex of young, normal, asymptomatic people and precedes the onset of amyloid accumulation<sup>38</sup>. With age, hippocampal neurofibrillary tau pathology is nearly ubiquitous, but remains confined to limbic regions in cognitively normal, amyloid-free individuals<sup>39,40</sup>. However, tau appears to spread into neocortical regions almost solely in people with coexistent A $\beta$  pathology<sup>39,41</sup>. These individuals generally go on to develop AD dementia. In several studies examining the cognitively normal elderly or patients with mild cognitive impairment or AD, widespread cortical tau pathology (Braak stage  $\geq 3$ ) was commonly observed in patients with concomitant A $\beta$  plaques; it was never observed in those without plaques, suggesting that the presence of A $\beta$  aggregation is required for the appearance of high-grade cortical tau pathology<sup>39,41,42</sup>. Furthermore, although hippocampal

tau phosphorylation is commonly observed in cognitively normal adults, studies have found no evidence of neuronal loss in these regions with normal aging<sup>43,44</sup>. However, neurodegeneration does occur prominently in these regions in AD patients with amyloid plaques<sup>43,44</sup>, suggesting that tau-mediated toxicity again requires some trigger from A $\beta$ . Accordingly, ‘neuritic plaques’, which are amyloid plaques with associated neurofibrillary tau pathology, correlate more closely with neuronal loss and dementia in AD than either plaques or tangles alone<sup>45</sup>. These neuropathologic observations support the idea that while fibrillar A $\beta$  and neurofibrillary tau pathologies are anatomically separated, A $\beta$  aggregation appears to somehow result in accelerated neurofibrillary tau pathology and neuronal toxicity. As noted above, fAD mutations, which directly influence A $\beta$  aggregation, cause tau pathology that is similar to that seen in sAD and correlates closely with neuronal death. However, although mutations in the gene encoding tau (*Mapt*) cause neurodegenerative disease, they do not induce A $\beta$  pathology<sup>46,47</sup>. Accordingly, polymorphisms in *Mapt* are associated with increased CSF phospho-tau levels, but only in patients with CSF evidence of A $\beta$  pathology<sup>48</sup>. Thus, human neuropathological data supports a key tenet of the amyloid hypothesis: that A $\beta$  triggers or exacerbates downstream tau pathology, although it appears to do so without anatomic colocalization.

Preclinical data from cell culture and animal experiments also support A $\beta$  as the initiator of tau pathology and downstream neuronal injury. Exposure of primary mouse neuronal cultures to aggregated A $\beta$  species, derived either from synthetic A $\beta$  or isolated from human brain, induces tau phosphorylation, neuritic damage and dendritic spine loss<sup>49,50</sup>. Notably, tau knockout neurons were resistant to neuritic degeneration induced by synthetic or human-derived A $\beta$  species, whereas tau overexpression exacerbated A $\beta$ -induced damage<sup>51,52</sup>. It is notable that a developmental effect of tau deletion cannot be excluded in these and other experiments, as experiments using postnatal tau deletion have not been reported. In human neurons grown in a matrigel culture system, expression of fAD mutation-bearing APP elicited extracellular A $\beta$  aggregation and caused subsequent tau pathology<sup>53</sup>. This tau pathology could be blocked with  $\beta$ - or  $\gamma$ -secretase inhibitors, illustrating the dependence on APP cleavage. In mice, coexpression of mutant human APP and MAPT caused increased severity and spread of neurofibrillary tau pathology, but did not alter A $\beta$  pathology, again demonstrating that A $\beta$  aggregation appears upstream of tau<sup>54,55</sup>. Accordingly, injection of synthetic A $\beta$  fibrils into the brain of mutant human tau-expressing mice led to markedly increased tau pathology<sup>56</sup>. A $\beta$  also impairs axonal transport in cultured neurons in a tau-dependent manner, whereas behavioral deficits observed in human APP-expressing mice were alleviated by tau deletion. Again, in these experiments, tau had no effect on A $\beta$  pathology<sup>57,58</sup>. In total, substantial preclinical data demonstrates that A $\beta$  species can directly trigger tau pathology in cells and mice, whereas human neuropathologic data supports a model in which tau pathology does not spread into the neocortex until after substantial A $\beta$  pathology has developed. A $\beta$  aggregation appears to somehow be triggering an exacerbation of tauopathy, which may in turn cause neuronal dysfunction and death. Although A $\beta$  and tau pathology are anatomically separate in the AD brain, considerable evidence demonstrates that A $\beta$  can still trigger tau pathology and neurodegeneration in regions with minimal fibrillar A $\beta$  pathology.

Induction of toxic protein misfolding by A $\beta$  is not isolated to tau. Many individuals with either fAD or sAD also develop  $\alpha$ -synuclein aggregation in limbic and cortical regions, suggesting that A $\beta$  may also accelerate synuclein pathology<sup>59,60</sup>. Accordingly, preclinical models demonstrate that A $\beta$  can induce synuclein pathology<sup>61,62</sup>. TDP-43

pathology is also commonly seen in AD patients and may contribute to neurodegeneration<sup>63</sup>. Thus, the ability of A $\beta$  to induce misfolding of other toxic proteins, such as tau, synuclein and TDP-43, may be critical for AD pathogenesis, although the exact contribution of some of these protein aggregates is not fully understood.

#### Tau pathology and neurodegeneration: temporal discord

Temporal discrepancy between the appearance of amyloid plaques, tau tangles, neuronal loss and clinical dementia is another point of frequent contention with the amyloid hypothesis. Many clinically asymptomatic older individuals are known to have substantial amyloid plaque pathology, either at autopsy or by PET imaging. Critics claim that this shows that A $\beta$  does not cause dementia. Again, it should be noted that fAD patients also develop fibrillar amyloid plaque pathology years before symptom onset, but clearly have A $\beta$ -driven disease<sup>15</sup>. Large cross-sectional biomarker studies suggest that amyloid plaque pathology is not asymptomatic, but instead represents preclinical AD, although the pathologic 'incubation time' between the appearance of plaques and onset of tau pathology can be several years, and the time to onset of clinical dementia can be over a decade<sup>64–68</sup>. Emerging longitudinal evidence from several groups supports this concept, as asymptomatic individuals with biomarker evidence solely of amyloid plaques (either by CSF or PET amyloid imaging markers, with no tau or other cell injury markers) are ~4-fold more likely than those without plaques to develop clinical dementia within the ensuing 2–7 years, although the length of follow up is likely still too short to fully appreciate this risk<sup>66–71</sup>. If amyloid plaques are present and there is biomarker evidence of brain injury (such as decrease glucose uptake, hippocampal atrophy or elevated CSF tau), risk of conversion to clinical dementia is even higher, with relative risks exceeding 10 (refs. 66,67,71,72). People who are ostensibly cognitively normal but have amyloid plaques also exhibit very subtle cognitive deficits on detailed neuropsychometric testing and accelerated hippocampal atrophy when compared with plaque-free controls, suggesting that A $\beta$  deposition may cause a mild, but progressive, pathological state before the onset of more rampant neurodegeneration with tauopathy and synucleinopathy<sup>73,74</sup>. Although not conclusive evidence of the central role of A $\beta$  in AD, the bulk of human biomarker data supports the amyloid hypothesis, as A $\beta$ -related changes precede tau biomarker changes and cognitive markers by years, are associated with mild, but progressive, neuropathology, and are predictive of subsequent dementia.

#### How does A $\beta$ initiate AD pathology?

So how do we reconcile this anatomic and temporal discordance between fibrillar A $\beta$  pathology, tau aggregation and neurodegeneration in both fAD and sAD? One explanation is that in addition to fibrillar plaques, oligomeric forms of A $\beta$  may mediate further pathology in AD. Indeed, a variety of cytotoxic oligomeric A $\beta$  species have been identified in AD brain lysates which can exert a wide variety of pathogenic effects *in vitro* and in the mouse brain<sup>75–77</sup>. These oligomeric A $\beta$  species do not necessarily correlate temporally or spatially with plaques, and can be purified from brain regions which are subject to intense neuronal loss, such as the hippocampus<sup>78–80</sup>. Indeed, there is some evidence that the presence of A $\beta$  oligomers predicts the presence of dementia more accurately than plaque burden<sup>78,80</sup>. In humans, A $\beta$  oligomers appear to accumulate with age, and are correlated with the appearance of tau pathology<sup>81,82</sup>. Mice which accumulate A $\beta$  oligomers but not fibrillar plaques also develop synaptic damage, inflammation and cognitive impairment<sup>83,84</sup>. However, it is difficult to rectify the oligomer hypothesis with the long prodromal phase of human AD during which plaques are

evident but significant neurodegeneration is not, or to explain why oligomers would not lead to more significant neuronal loss in animal models of A $\beta$  deposition. Furthermore, the specific species of A $\beta$  which mediate downstream pathology remain an open question<sup>75,85</sup>. While the direct neurotoxicity of A $\beta$  oligomers *in vivo* is unclear, these species have been shown to directly initiate tau phosphorylation both *in vitro* and *in vivo*<sup>52,83,86</sup>. At a molecular level, oligomeric A $\beta$  may initiate tauopathy through specific signaling events in neurons, such as activation of the Src kinase Fyn<sup>58,87,88</sup>, inducing proteases which modify tau<sup>89</sup>, or activating specific tau-targeting kinases<sup>90</sup>, though none of these have been adequately demonstrated in humans.

Given increasing evidence that A $\beta$ , tau and  $\alpha$ -synuclein aggregates all have prion-like properties and can potentially seed normal forms of these proteins and spread through the brain, it may also be important to investigate the ability of A $\beta$  species to exacerbate the prion-like spread of tau and synuclein<sup>91–96</sup>. Finally, A $\beta$  could cause large-scale alterations in the brain's ability to maintain proper protein quality control (proteostasis), eventually prompting aggregation of tau, synuclein and other intracellular proteins and causing toxicity<sup>97–99</sup>. Proteostatic failure could explain  $\alpha$ -synuclein in the brains of fAD patients, many of whom are too young to have accumulated such deposits as a function of age, or coexistent  $\alpha$ -synuclein and TDP-43 aggregates in sAD patients<sup>63</sup>. A $\beta$ -induced aggregation and subsequent propagation and cross-templating of other toxic proteins could overwhelm proteostatic mechanisms. As many cytoprotective and proteostatic systems in neurons and glial decline with age, aging might thus set the stage for disseminated A $\beta$  toxicity<sup>100,101</sup>. Other age-related effects or comorbid pathologies (such as diabetes, head trauma, oxidative stress, inflammation, vascular factors, or even sleep deprivation) might influence the rate of A $\beta$  aggregation and accumulation, accelerate the rate at which A $\beta$  triggers downstream pathology, or directly exacerbate downstream pathology, thereby modulating the onset of dementia.

#### A $\beta$ does not operate in a vacuum

A shortcoming of the initial amyloid hypothesis is the suggestion that A $\beta$  itself could directly cause the panoply of pathologic changes observed in AD. A $\beta$  critics have frequently and correctly pointed out the many other destructive phenomena, from oxidative stress to impaired autophagy, that occur in AD brain. Certainly when one uses the clinical endpoint of cognitive impairment, many factors appear to accelerate AD, cerebrovascular disease being foremost among them. The relationship between these factors, A $\beta$  and neurodegeneration is unclear. Mice harboring fAD mutations develop neuroinflammation, oxidative stress, mitochondrial dysfunction and other pathologic alterations that appear to be downstream changes that indicate A $\beta$ -induced neuronal or glial injury, although some of these markers appear before substantial plaque deposition<sup>102–104</sup>. However, preclinical data suggest that neuronal stressors, such as oxidative and nitrative stress<sup>105,106</sup>, mitochondrial dysfunction<sup>107</sup> and inflammation<sup>108</sup>, can also directly influence APP metabolism and A $\beta$  accumulation, indicating the existence of a possible feedforward mechanism by which A $\beta$ -induced injury can facilitate A $\beta$  production, or by which other stressors, such as ischemia or trauma, might exacerbate A $\beta$  production and toxicity.

Although it may be tempting to implicate these other processes as the causative factors in AD, it is important to consider that A $\beta$  plaque pathology is uniquely indicative of the clinical syndrome of AD, whereas oxidative damage, inflammation, mitochondrial dysfunction and other pathogenic markers are observed in many neurologic diseases. Furthermore, there is no strong evidence from humans that genetic mutations that increase oxidative stress, inflammation, mitochondrial



dysfunction or inhibit autophagy lead to A $\beta$  pathology in the brain. Risk factors such as smoking can have A $\beta$ -dependent and A $\beta$ -independent effects on AD pathogenesis, as smoking causes systemic oxidative stress, vascular injury and may increase A $\beta$  accumulation<sup>109,110</sup>. Similarly, polymorphisms in *TREM2* affect microglial activation and increase the risk of AD, yet *TREM2* hemizygous mice have no increase in A $\beta$  plaques, suggesting that microglial dysfunction could influence AD pathogenesis independently of the amount of A $\beta$  accumulation<sup>111</sup>. In both cases, it is likely that these risk factors influence pathogenic mechanism downstream of A $\beta$  and are not unique to AD. Accordingly, smoking increases the risk of many diseases of the brain, including vascular dementia, whereas *TREM2* likely does the same (it has recently been linked to increased risk of ALS, frontotemporal dementia and Parkinson disease)<sup>112,113</sup>. It would be foolish to argue that these many processes are not important in AD, as they clearly contribute to disease pathogenesis and might provide excellent therapeutic targets. But the existence of these other mechanisms of neural injury in AD does not mean that they are causative, nor does it negate the central importance of A $\beta$ .

Another alternative concept of AD pathogenesis suggests that APP cleavage is indeed critical to AD, but that APP fragments other than A $\beta$  are the pathogenic species. Mice with inducible expression of APP develop A $\beta$  plaques and cognitive impairment. The cognitive impairment resolved in part when the APP transgene expression was turned off, despite persisting A $\beta$  plaques<sup>114</sup>. Conversely, mice that express A $\beta$  from a truncated transgene (and not full-length APP) accumulate multiple A $\beta$  species as well as plaques, but do not develop cognitive impairment<sup>115</sup>. Several studies have implicated the APP  $\beta$ -C-terminal fragment ( $\beta$ -CTF) as a possible mediator of cognitive impairment in APP-overexpressing mice<sup>116,117</sup>. However, it should be noted that antibodies targeting A $\beta$  reduce plaque burden and rescue cognition in APP transgenic mice without eliminating plaques<sup>118</sup>. Moreover, as mentioned earlier, APP mutations in the A $\beta$  coding region that enhance A $\beta$  aggregation without influencing APP cleavage still cause human fAD<sup>5,6</sup>. Thus, the data implicating alternative APP fragments in AD is intriguing, but it is still largely restricted to mouse models and does not discount the contribution of A $\beta$ .

APP is a complex molecule with a variety of neurobiological functions<sup>119</sup>. Thus, it is important to note that cognitive and behavioral changes in APP-overexpressing mice are not fully correlated with A $\beta$  pathology and are likely to be greatly influenced by both the APP transgene and marked overexpression from the promoter used. Cognitive impairment in APP mice can appear before, after or without substantial A $\beta$  deposition, and is generally reversible<sup>85,118</sup>. In human AD, however, cognitive decline is notable years or even decades after extensive plaque pathology accumulates, is almost always associated with the onset of tau pathology and neurodegeneration, and has not been shown to be reversible. Thus, the nature of cognitive impairment in mouse APP models and humans may be fundamentally different, and mouse results should be interpreted carefully.

### What initiates A $\beta$ aggregation?

If A $\beta$  is the initiator of AD pathology, what initially triggers the aggregation and accumulation of A $\beta$  in sAD? How is this related to age? Currently, we have no iron-clad explanation for why A $\beta$  initially accumulates and forms plaques in sAD or why this pathology occurs late in life. A $\beta$  might accumulate in a concentration-dependent manner throughout life, with increased neuronal activity in certain brain regions leading to excessive A $\beta$  production, ultimately causing aggregation and seed formation that then propagates<sup>91,120</sup>. Factors that enhance A $\beta$  production or aggregation or that suppress A $\beta$  clearance could contribute to this over a lifetime. Impaired sleep-wake cycle, for


example, could contribute to gradual A $\beta$  accumulation by promoting a higher level of neuronal A $\beta$  release and by disrupting normal diurnal oscillations in extracellular A $\beta$  levels<sup>121</sup>. Sleep deprivation could also impair the clearance of A $\beta$  from the brain by bulk fluid movement, or 'glymphatic' flow<sup>122</sup>. As another example, age-related oxidative and nitrate stress could also exert a gradual influence on A $\beta$  production by altering secretase function<sup>105,106</sup> and by promoting A $\beta$  aggregation through oxidative modification of the peptide<sup>123,124</sup>. Another possibility is that age-related decline in the clearance of A $\beta$  causes initial A $\beta$  accumulation. Glial uptake of A $\beta$ , as well as the aforementioned glymphatic bulk-flow removal of proteins from the brain, both decline with age<sup>125,126</sup>. Studies in humans have shown diminished A $\beta$  clearance in AD patients<sup>127</sup>, although this has not yet been demonstrated to precede plaque deposition. Age-related disturbances in proteostasis and neuronal stress response signaling might also shift the balance of A $\beta$  metabolism toward aggregation<sup>100,101,128</sup>.

We propose a model in which A $\beta$  serves as the primary initiator of AD pathogenesis (Fig. 1). In our model, A $\beta$  levels exist in a carefully orchestrated homeostasis throughout life, and factors during middle age that disturb that balance facilitate A $\beta$  aggregation. These factors include increased synaptic activity and sleep disruption, which lead to increased A $\beta$  release, psychological stress (which can increase A $\beta$  production via different mechanisms), the function or genotype of proteins (for example, ApoE, Lrp1 and SorL1) that regulate A $\beta$  trafficking and clearance, age-related declines in A $\beta$  clearance mechanisms, and cellular stressors such as reactive oxygen species and ischemia that might facilitate A $\beta$  production or aggregation. As A $\beta$  homeostasis is lost, oligomeric and fibrillar A $\beta$  species begin to accumulate, and the first plaques appear, providing the first biomarker evidence of AD in humans, although the patient remains clinically asymptomatic. After several years of A $\beta$  aggregation, A $\beta$  somehow triggers the acceleration of AD-type tau pathology, as neurofibrillary tangles begin to spread outside the limbic system and into the neocortex, prompting increases in neurodegeneration that are reflected as an increase in CSF tau and p-tau levels as well as other neuronal markers (for example, VILIP-1)<sup>72</sup>. This 'tau trigger' event is still poorly understood and may be mediated by the appearance of particular toxic A $\beta$  species, the activation of an intermediary signaling process or kinase cascade, or changes in the innate immune system. These events may lead to a breaking point at which the proteostatic capacity of the brain has been overwhelmed, facilitating tau aggregation and spreading. Aggregation of other toxic proteins such as synuclein and TDP-43 may also begin at this stage. At this point, the cascade is set in full motion, as neuronal loss, oxidative damage, inflammation and clinical symptoms become evident, and neutralizing or removing A $\beta$  is less likely to have a major effect. Age-related factors and comorbid pathologies likely contribute to the occurrence of AD by injuring neurons in parallel with A $\beta$  and tau, thereby accelerating the appearance of symptoms, although some such factors may directly regulate A $\beta$  levels or affect the A $\beta$ -tau interaction. Thus, preventative strategies for AD would focus on treatment of conditions that promote A $\beta$  accumulation in middle age (for example, sleep disorders). Anti-A $\beta$  therapies would need to be delivered as early in the process as possible, whereas the appearance of positive A $\beta$  biomarkers would be most helpful for timing the initiation of therapies targeting downstream pathologies, such as anti-tau agents.

### Has the amyloid hypothesis been tested pharmacologically?

Mention of AD therapeutics elicits one of the more recent arguments against the amyloid hypothesis: the failure of clinical trials targeting A $\beta$ . The possibility that A $\beta$  initiates pathology very early

**Figure 1** An updated framework of the amyloid hypothesis. The black arrows illustrate the processing of APP by  $\beta$ - and  $\gamma$ -secretases to yield  $A\beta$  species, which subsequently aggregate, ultimately triggering tau aggregation and downstream toxicity. Blue text and arrows illustrate proposed modifiers of the  $A\beta$  cascade, and red text and arrows show the influence of aging and comorbid pathologies. Note that several feedforward cycles are hypothesized, including one involving disturbed sleep promoting  $A\beta$  production (and perhaps  $A\beta$  clearance, although not depicted), whereas  $A\beta$  aggregation in turn disrupts sleep cycles. Multiple factors, from aging to oxidative stress, contribute to proteostatic failure, which in turn promotes aggregation of  $A\beta$ , tau and likely other toxic proteins. Many of the  $A\beta$ -modifying factors interact with each other (such as ApoE modulating inflammation), although this is not depicted. IDE, insulin-degrading enzyme; ROS, reactive oxygen species; TBI, traumatic brain injury.



in the disease suggests that only early anti- $A\beta$  therapy is likely to be effective, and, to date, no completed trials have attempted therapy early in the  $A\beta$  cascade. Furthermore,  $A\beta$  target engagement has not yet been adequate to truly test the amyloid hypothesis. The Elan AN1792 active  $A\beta$  immunization study (which was halted as a result of several cases of meningoencephalitis) is often cited as an indictment of the amyloid hypothesis, as several remaining patients were followed after immunization and failed to show any clinical benefit despite evidence of reduced plaque burden at autopsy<sup>129</sup>. However, these patients were immunized late in the course of disease, well after dementia was clinically apparent, and the small sample size in a phase I trial primarily assessing safety that was aborted after only a few vaccinations at most makes it difficult to draw any firm conclusions from this work. If one insists on considering this data, it should be noted that analysis of this same cohort did show a modest decrease in tau pathology, while surviving immunized participants had a slight improvement in functional outcomes, despite late treatment initiation<sup>130–132</sup>. Ongoing studies, however, may put the amyloid hypothesis to a much more rigorous test. The Dominantly Inherited Alzheimer Network (DIAN) treatment trial and Alzheimer's Prevention Initiative (API) should address the role of  $A\beta$  in fAD most directly, as both are designed to test if anti-amyloid therapy in primarily presymptomatic fAD patients can prevent pathologic changes and dementia<sup>133,134</sup>. This represents the earliest therapy that is currently possible and employs a patient population with more 'pure'  $A\beta$ -driven disease. However, one concerning possibility that arises from the  $A\beta$  as initiator hypothesis is that the appearance of fibrillar  $A\beta$  pathology could represent a point in the pathogenic cascade that is already too late for effective anti- $A\beta$  therapy. Ultimately, prior prevention of  $A\beta$  deposition could prove to be the most effective treatment to target  $A\beta$ , but whether such an approach will be tested is unclear. These studies, along with similar trials in sAD, such as the A4 trial, may dictate, in part, the future of  $A\beta$ -targeted therapies.

There are also several ongoing trials in very mild and mild dementia resulting from AD using either BACE inhibition or anti- $A\beta$  antibodies that will also be very important to evaluate. Considering the therapeutic regimens employed in diseases such as diabetes, coronary atherosclerosis and cancer, it seems reasonable that a multi-target therapeutic approach will be needed for AD, with the selection of targets dictated by the stage of the pathology. Thus, regardless of the accuracy of the amyloid hypothesis, target elucidation and therapy development for a variety of pathogenic processes in AD, from tau aggregation to microglial activation to mitochondrial dysfunction, is critical.

**Conclusions**

In the past 22 years, it has become clear that the idea that  $A\beta$  causes AD via a simple, linear model of toxicity is very likely incorrect. Our

interpretation of the data places  $A\beta$  not as the primary direct neurotoxin that itself alone causes AD, but rather as the initiator of a complex network of pathologic changes in the brain, many of them tau-dependent, that culminates years later in neurodegeneration. To successfully forestall the progression of this cascade, multiple therapies targeting several nodes of the neurodegenerative network may be needed, and the timing of these therapies in the disease progression will likely be critical. Many important questions remain to be answered.

What instigates  $A\beta$  aggregation in sAD? Are there earlier precipitating events that precede  $A\beta$  aggregation and are related to age or other disease processes? How can we prevent this?

How does  $A\beta$  aggregation trigger spread of tau and synuclein pathology in the human brain? Are there specific therapeutic targets to prevent this process?

At what point in the cascade is it too late to intervene by targeting  $A\beta$ ? Once  $A\beta$  plaques are apparent by imaging or CSF studies, has  $A\beta$  already triggered the critical downstream cascades?

Which downstream pathologies are legitimate therapeutic targets and which are epiphenomena? Post-mortem AD brain tissue reveals a dizzying array of cellular and biochemical alterations, but which can be successfully targeted to mitigate disease?

What is the pathogenesis of AD-like dementias without amyloid plaques (such as suspected non-amyloid pathology, SNAP), or 'tangle-predominant AD'? Are these new subtypes of dementia that appear clinically similar to AD or biologically separate entities that will require unique therapeutic approaches? If there are no plaques, should we still call it AD?

The answers to these questions, as well the outcomes of the many anti- $A\beta$  therapeutic trials currently in progress, should bring us closer to a comprehensive understanding of the role and therapeutic potential of  $A\beta$  in AD, and guide the development of the next generation of AD therapeutic regimens.

**ACKNOWLEDGMENTS**

E.S.M. is supported by NINDS grant K08NS079405 and Alzheimer's Association grant NIRG-305476. D.M.H. is supported by NIH grants R01 NS090934, R01 AG047644, P01 NS074969, P01 NS080675, PO1-AG03991, R01 NS034467, P01-AG026276, and U01 AG032438 and from the Tau Consortium and Cure Alzheimer's Fund.

**COMPETING FINANCIAL INTERESTS**

The authors declare competing financial interests: details are available in the [online version of the paper](#).

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

1. Hardy, J.A. & Higgins, G.A. Alzheimer's disease: the amyloid cascade hypothesis. *Science* **256**, 184–185 (1992).
2. Bettens, K., Sleegers, K. & Van Broeckhoven, C. Genetic insights in Alzheimer's disease. *Lancet Neurol.* **12**, 92–104 (2013).
3. Levy, E. *et al.* Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. *Science* **248**, 1124–1126 (1990).
4. Goate, A. *et al.* Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature* **349**, 704–706 (1991).
5. Tsubuki, S., Takaki, Y. & Saido, T.C. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. *Lancet* **361**, 1957–1958 (2003).
6. Tomiyama, T. *et al.* A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. *Ann. Neurol.* **63**, 377–387 (2008).
7. Rovelet-Lecrux, A. *et al.* APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. *Nat. Genet.* **38**, 24–26 (2006).
8. Sleegers, K. *et al.* APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. *Brain* **129**, 2977–2983 (2006).
9. Cabrejo, L. *et al.* Phenotype associated with APP duplication in five families. *Brain* **129**, 2966–2976 (2006).
10. Prasher, V.P. *et al.* Molecular mapping of Alzheimer-type dementia in Down's syndrome. *Ann. Neurol.* **43**, 380–383 (1998).
11. Citron, M. *et al.* Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. *Nature* **360**, 672–674 (1992).
12. Eckman, C.B. *et al.* A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). *Hum. Mol. Genet.* **6**, 2087–2089 (1997).
13. Chávez-Gutiérrez, L. *et al.* The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. *EMBO J.* **31**, 2261–2274 (2012).
14. Shephard, C., McCann, H. & Halliday, G.M. Variations in the neuropathology of familial Alzheimer's disease. *Acta Neuropathol.* **118**, 37–52 (2009).
15. Bateman, R.J. *et al.* Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *N. Engl. J. Med.* **367**, 795–804 (2012).
16. Ryman, D.C. *et al.* Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. *Neurology* **83**, 253–260 (2014).
17. Corder, E.H. *et al.* Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* **261**, 921–923 (1993).
18. Chiang, G.C. *et al.* Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects. *Neurology* **75**, 1976–1981 (2010).
19. Verghese, P.B., Castellano, J.M. & Holtzman, D.M. Apolipoprotein E in Alzheimer's disease and other neurological disorders. *Lancet Neurol.* **10**, 241–252 (2011).
20. Castellano, J.M. *et al.* Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. *Sci. Transl. Med.* **3**, 89ra57 (2011).
21. Fagan, A.M. *et al.* Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. *Neurobiol. Dis.* **9**, 305–318 (2002).
22. Hudry, E. *et al.* Gene transfer of human ApoE isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. *Sci. Transl. Med.* **5**, 212ra161 (2013).
23. Morris, J.C. *et al.* APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. *Ann. Neurol.* **67**, 122–131 (2010).
24. Vemuri, P. *et al.* Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. *Ann. Neurol.* **67**, 308–316 (2010).
25. Verghese, P.B. *et al.* ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. *Proc. Natl. Acad. Sci. USA* **110**, E1807–E1816 (2013).
26. Bales, K.R. *et al.* Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. *Nat. Genet.* **17**, 263–264 (1997).
27. Bien-Ly, N., Gillespie, A.K., Walker, D., Yoon, S.Y. & Huang, Y. Reducing human apolipoprotein E levels attenuates age-dependent Abeta accumulation in mutant human amyloid precursor protein transgenic mice. *J. Neurosci.* **32**, 4803–4811 (2012).
28. Kim, J. *et al.* Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. *J. Neurosci.* **31**, 18007–18012 (2011).
29. Kim, J. *et al.* Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Abeta amyloidosis. *J. Exp. Med.* **209**, 2149–2156 (2012).
30. Sunderland, T. *et al.* Cerebrospinal fluid beta-amyloid1–42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. *Biol. Psychiatry* **56**, 670–676 (2004).
31. Jonsson, T. *et al.* A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. *Nature* **488**, 96–99 (2012).
32. Braak, H. & Braak, E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol.* **82**, 239–259 (1991).
33. Serrano-Pozo, A., Frosch, M.P., Masliah, E. & Hyman, B.T. Neuropathological alterations in Alzheimer disease. *Cold Spring Harb. Perspect. Med.* **1**, a006189 (2011).
34. Gómez-Isla, T. *et al.* Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. *Ann. Neurol.* **41**, 17–24 (1997).
35. Arriagada, P.V., Marzloff, K. & Hyman, B.T. Distribution of Alzheimer-type pathological changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. *Neurology* **42**, 1681–1688 (1992).
36. Arriagada, P.V., Growdon, J.H., Hedley-Whyte, E.T. & Hyman, B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. *Neurology* **42**, 631–639 (1992).
37. Price, J.L., Davis, P.B., Morris, J.C. & White, D.L. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. *Neurobiol. Aging* **12**, 295–312 (1991).
38. Braak, H. & Del Tredici, K. The pathological process underlying Alzheimer's disease in individuals under thirty. *Acta Neuropathol.* **121**, 171–181 (2011).
39. Price, J.L. & Morris, J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. *Ann. Neurol.* **45**, 358–368 (1999).
40. Elobeid, A., Soininen, H. & Alafuzoff, I. Hyperphosphorylated tau in young and middle-aged subjects. *Acta Neuropathol.* **123**, 97–104 (2012).
41. Knopman, D.S. *et al.* Neuropathology of cognitively normal elderly. *J. Neuropathol. Exp. Neurol.* **62**, 1087–1095 (2003).
42. Petersen, R.C. *et al.* Neuropathologic features of amnesic mild cognitive impairment. *Arch. Neurol.* **63**, 665–672 (2006).
43. Gómez-Isla, T. *et al.* Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. *J. Neurosci.* **16**, 4491–4500 (1996).
44. West, M.J., Coleman, P.D., Flood, D.G. & Troncoso, J.C. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. *Lancet* **344**, 769–772 (1994).
45. Tiraboschi, P., Hansen, L.A., Thal, L.J. & Corey-Bloom, J. The importance of neuritic plaques and tangles to the development and evolution of AD. *Neurology* **62**, 1984–1989 (2004).
46. Reed, L.A. *et al.* Autosomal dominant dementia with widespread neurofibrillary tangles. *Ann. Neurol.* **42**, 564–572 (1997).
47. Lindquist, S.G. *et al.* Alzheimer disease-like clinical phenotype in a family with FTDP-17 caused by a MAPT R406W mutation. *Eur. J. Neurol.* **15**, 377–385 (2008).
48. Kauwe, J.S. *et al.* Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. *Proc. Natl. Acad. Sci. USA* **105**, 8050–8054 (2008).
49. Ferreira, A., Lu, Q., Orecchio, L. & Kosik, K.S. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta. *Mol. Cell. Neurosci.* **9**, 220–234 (1997).
50. Zempel, H., Thies, E., Mandelkow, E. & Mandelkow, E.M. Abeta oligomers cause localized Ca(2+) elevation, misrouting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. *J. Neurosci.* **30**, 11938–11950 (2010).
51. Rapoport, M., Dawson, H.N., Binder, L.I., Vitek, M.P. & Ferreira, A. Tau is essential to beta -amyloid-induced neurotoxicity. *Proc. Natl. Acad. Sci. USA* **99**, 6364–6369 (2002).
52. Jin, M. *et al.* Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. *Proc. Natl. Acad. Sci. USA* **108**, 5819–5824 (2011).
53. Choi, S.H. *et al.* A three-dimensional human neural cell culture model of Alzheimer's disease. *Nature* **515**, 274–278 (2014).
54. Hurtado, D.E. *et al.* A(beta) accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. *Am. J. Pathol.* **177**, 1977–1988 (2010).
55. Lewis, J. *et al.* Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. *Science* **293**, 1487–1491 (2001).
56. Götz, J., Chen, F., van Dorpe, J. & Nitsch, R.M. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Abeta 42 fibrils. *Science* **293**, 1491–1495 (2001).
57. Roberson, E.D. *et al.* Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. *Science* **316**, 750–754 (2007).
58. Roberson, E.D. *et al.* Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. *J. Neurosci.* **31**, 700–711 (2011).
59. Lippa, C.F. *et al.* Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. *Am. J. Pathol.* **153**, 1365–1370 (1998).
60. Hashimoto, M. & Masliah, E. Alpha-synuclein in Lewy body disease and Alzheimer's disease. *Brain Pathol.* **9**, 707–720 (1999).
61. Masliah, E. *et al.* beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. *Proc. Natl. Acad. Sci. USA* **98**, 12245–12250 (2001).
62. Larson, M.E. *et al.* Soluble alpha-synuclein is a novel modulator of Alzheimer's disease pathophysiology. *J. Neurosci.* **32**, 10253–10266 (2012).
63. Josephs, K.A. *et al.* TDP-43 is a key player in the clinical features associated with Alzheimer's disease. *Acta Neuropathol.* **127**, 811–824 (2014).
64. Jack, C.R. Jr. *et al.* Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurol.* **12**, 207–216 (2013).
65. Jack, C.R. Jr. *et al.* Evidence for ordering of Alzheimer disease biomarkers. *Arch. Neurol.* **68**, 1526–1535 (2011).



66. Roe, C.M. *et al.* Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. *Neurology* **80**, 1784–1791 (2013).
67. Vos, S.J. *et al.* Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. *Lancet Neurol.* **12**, 957–965 (2013).
68. Villemagne, V.L. *et al.* Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. *Lancet Neurol.* **12**, 357–367 (2013).
69. Chen, X. *et al.* Pittsburgh compound B retention and progression of cognitive status—a meta-analysis. *Eur. J. Neurol.* **21**, 1060–1067 (2014).
70. Villemagne, V.L. *et al.* Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. *Ann. Neurol.* **69**, 181–192 (2011).
71. Knopman, D.S. *et al.* Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. *Neurology* **78**, 1576–1582 (2012).
72. Tarawneh, R. *et al.* Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. *Ann. Neurol.* **70**, 274–285 (2011).
73. Donohue, M.C. *et al.* The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. *JAMA Neurol.* **71**, 961–970 (2014).
74. Chételat, G. *et al.* Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition. *Neurology* **78**, 477–484 (2012).
75. Shankar, G.M. *et al.* Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat. Med.* **14**, 837–842 (2008).
76. Walsh, D.M. *et al.* Naturally secreted oligomers of amyloid beta protein potentially inhibit hippocampal long-term potentiation *in vivo*. *Nature* **416**, 535–539 (2002).
77. Mucke, L. & Selkoe, D.J. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. *Cold Spring Harb. Perspect. Med.* **2**, a006338 (2012).
78. Esparza, T.J. *et al.* Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. *Ann. Neurol.* **73**, 104–119 (2013).
79. Tomic, J.L., Pensalfini, A., Head, E. & Glabe, C.G. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. *Neurobiol. Dis.* **35**, 352–358 (2009).
80. McLean, C.A. *et al.* Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. *Ann. Neurol.* **46**, 860–866 (1999).
81. Lesné, S.E. *et al.* Brain amyloid-beta oligomers in ageing and Alzheimer's disease. *Brain* **136**, 1383–1398 (2013).
82. Handoko, M. *et al.* Correlation of specific amyloid-beta oligomers with tau in cerebrospinal fluid from cognitively normal older adults. *JAMA Neurol.* **70**, 594–599 (2013).
83. Zhang, Y. *et al.* A lifespan observation of a novel mouse model: *in vivo* evidence supports abeta oligomer hypothesis. *PLoS ONE* **9**, e85885 (2014).
84. Tomiyama, T. *et al.* A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss *in vivo*. *J. Neurosci.* **30**, 4845–4856 (2010).
85. Lesné, S. *et al.* A specific amyloid-beta protein assembly in the brain impairs memory. *Nature* **440**, 352–357 (2006).
86. Ma, Q.L. *et al.* Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. *J. Neurosci.* **29**, 9078–9089 (2009).
87. Ittner, L.M. *et al.* Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. *Cell* **142**, 387–397 (2010).
88. Haass, C. & Mandelkow, E. Fyn-tau-amyloid: a toxic triad. *Cell* **142**, 356–358 (2010).
89. Zhang, Z. *et al.* Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. *Nat. Med.* **20**, 1254–1262 (2014).
90. Martin, L. *et al.* Tau protein kinases: involvement in Alzheimer's disease. *Ageing Res. Rev.* **12**, 289–309 (2013).
91. Meyer-Luehmann, M. *et al.* Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. *Science* **313**, 1781–1784 (2006).
92. Sanders, D.W. *et al.* Distinct tau prion strains propagate in cells and mice and define different tauopathies. *Neuron* **82**, 1271–1288 (2014).
93. de Calignon, A. *et al.* Propagation of tau pathology in a model of early Alzheimer's disease. *Neuron* **73**, 685–697 (2012).
94. Liu, L. *et al.* Trans-synaptic spread of tau pathology *in vivo*. *PLoS ONE* **7**, e31302 (2012).
95. Guo, J.L. *et al.* Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. *Cell* **154**, 103–117 (2013).
96. Giasson, B.I. *et al.* Initiation and synergistic fibrillization of tau and alpha-synuclein. *Science* **300**, 636–640 (2003).
97. Dasuri, K., Zhang, L. & Keller, J.N. Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis. *Free Radic. Biol. Med.* **62**, 170–185 (2013).
98. De Strooper, B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. *Physiol. Rev.* **90**, 465–494 (2010).
99. Nixon, R.A. & Yang, D.S. Autophagy failure in Alzheimer's disease—locating the primary defect. *Neurobiol. Dis.* **43**, 38–45 (2011).
100. Taylor, R.C. & Dillin, A. Aging as an event of proteostasis collapse. *Cold Spring Harb. Perspect. Biol.* **3**, a004440 (2011).
101. Lu, T. *et al.* REST and stress resistance in ageing and Alzheimer's disease. *Nature* **507**, 448–454 (2014).
102. Praticò, D., Uryu, K., Leight, S., Trojanowski, J.Q. & Lee, V.M. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. *J. Neurosci.* **21**, 4183–4187 (2001).
103. Benzing, W.C. *et al.* Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. *Neurobiol. Aging* **20**, 581–589 (1999).
104. Calkins, M.J., Manczak, M., Mao, P., Shirendeb, U. & Reddy, P.H. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. *Hum. Mol. Genet.* **20**, 4515–4529 (2011).
105. Guix, F.X. *et al.* Modification of gamma-secretase by nitrosative stress links neuronal ageing to sporadic Alzheimer's disease. *EMBO Mol. Med.* **4**, 660–673 (2012).
106. Wahlster, L. *et al.* Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer's disease. *Acta Neuropathol.* **125**, 187–199 (2013).
107. Kukreja, L., Kujoth, G.C., Prolla, T.A., Van Leuven, F. & Vassar, R. Increased mtDNA mutations with aging promotes amyloid accumulation and brain atrophy in the APP/Ld transgenic mouse model of Alzheimer's disease. *Mol. Neurodegener.* **9**, 16 (2014).
108. Liu, Y. *et al.* IKKbeta deficiency in myeloid cells ameliorates Alzheimer's disease-related symptoms and pathology. *J. Neurosci.* **34**, 12982–12999 (2014).
109. Durazzo, T.C., Mattsson, N. & Weiner, M.W. Smoking and increased Alzheimer's disease risk: a review of potential mechanisms. *Alzheimers Dement.* **10**, S122–S145 (2014).
110. Moreno-Gonzalez, I., Estrada, L.D., Sanchez-Mejias, E. & Soto, C. Smoking exacerbates amyloid pathology in a mouse model of Alzheimer's disease. *Nat. Commun.* **4**, 1495 (2013).
111. Ulrich, J.D. *et al.* Altered microglial response to Abeta plaques in APPS1–21 mice heterozygous for TREM2. *Mol. Neurodegener.* **9**, 20 (2014).
112. Cady, J. *et al.* TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. *JAMA Neurol.* **71**, 449–453 (2014).
113. Rayaprolu, S. *et al.* TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. *Mol. Neurodegener.* **8**, 19 (2013).
114. Melnikova, T. *et al.* Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. *J. Neurosci.* **33**, 3765–3779 (2013).
115. Kim, J. *et al.* Normal cognition in transgenic BRI2-Abeta mice. *Mol. Neurodegener.* **8**, 15 (2013).
116. Berger-Sweeney, J. *et al.* Impairments in learning and memory accompanied by neurodegeneration in mice transgenic for the carboxyl-terminus of the amyloid precursor protein. *Brain Res. Mol. Brain Res.* **66**, 150–162 (1999).
117. Gao, Y. & Pimplikar, S.W. The gamma-secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus. *Proc. Natl. Acad. Sci. USA* **98**, 14979–14984 (2001).
118. Dodart, J.C. *et al.* Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. *Nat. Neurosci.* **5**, 452–457 (2002).
119. Zheng, H. & Koo, E.H. Biology and pathophysiology of the amyloid precursor protein. *Mol. Neurodegener.* **6**, 27 (2011).
120. Bero, A.W. *et al.* Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. *Nat. Neurosci.* **14**, 750–756 (2011).
121. Kang, J.E. *et al.* Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. *Science* **326**, 1005–1007 (2009).
122. Xie, L. *et al.* Sleep drives metabolite clearance from the adult brain. *Science* **332**, 373–377 (2013).
123. Siegel, S.J., Bieschke, J., Powers, E.T. & Kelly, J.W. The oxidative stress metabolite 4-hydroxynonenol promotes Alzheimer protofibril formation. *Biochemistry* **46**, 1503–1510 (2007).
124. Head, E. *et al.* Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome. *Neurobiol. Dis.* **8**, 792–806 (2001).
125. Kress, B.T. *et al.* Impairment of paravascular clearance pathways in the aging brain. *Ann. Neurol.* **76**, 845–861 (2014).
126. Zhao, W., Zhang, J., Davis, E.G. & Rebeck, G.W. Aging reduces glial uptake and promotes extracellular accumulation of Abeta from a lentiviral vector. *Front. Aging Neurosci.* **6**, 210 (2014).
127. Mawuenyega, K.G. *et al.* Decreased clearance of CNS beta-amyloid in Alzheimer's disease. *Science* **330**, 1774 (2010).
128. Hipp, M.S., Park, S.H. & Hartl, F.U. Proteostasis impairment in protein-misfolding and -aggregation diseases. *Trends Cell Biol.* **24**, 506–514 (2014).
129. Holmes, C. *et al.* Long-term effects of Abeta42 immunization in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. *Lancet* **372**, 216–223 (2008).
130. Boche, D. *et al.* Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. *Acta Neuropathol.* **120**, 13–20 (2010).
131. Serrano-Pozo, A. *et al.* Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. *Brain* **133**, 1312–1327 (2010).
132. Vellas, B. *et al.* Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. *Curr. Alzheimer Res.* **6**, 144–151 (2009).
133. Mills, S.M. *et al.* Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. *Rev. Neurol. (Paris)* **169**, 737–743 (2013).
134. Reiman, E.M. *et al.* Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. *J. Alzheimers Dis.* **26** (suppl. 3), 321–329 (2011).